Hepatitis B and C in the liver transplant recipient: Current understanding and treatment
Article first published online: 30 DEC 2003
Copyright © 2001 American Association for the Study of Liver Diseases
Supplement: Long-Term Management of the Liver Transplant Patient
Volume 7, Issue Supplement 11B, pages s87–s98, November 2001
How to Cite
Rosen, H. R. (2001), Hepatitis B and C in the liver transplant recipient: Current understanding and treatment. Liver Transpl, 7: s87–s98. doi: 10.1053/jlts.2001.28519
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Merit Review Grant, Washington, DC
- National Institutes of Health grants
- 1Liver disease related to chronic viral hepatitis is the leading indication for orthotopic liver transplantation (OLT) worldwide.
- 2The natural history of hepatitis B virus infection has been dramatically modified, and outcome has improved substantially in the last decade with the use of hepatitis B immunoglobulin and lamivudine.
- 3Hepatitis C virus (HCV) recurrence, defined by histological injury, is almost universal, and a subset of patients (20% to 30%) develops allograft cirrhosis by the fifth year post-OLT.
- 4Unfortunately, antiviral therapy for hepatitis C post-OLT, even when initiated preemptively before the development of histological recurrence in the first few weeks post-OLT, has failed to alter the natural history of HCV disease recurrence.
- 5HCV-related allograft cirrhosis is associated with a high rate of decompensation and mortality.